FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040897701> ?p ?o ?g. }

• W2040897701 endingPage "1402" @default.
• W2040897701 startingPage "1390" @default.
• W2040897701 abstract "Many patients with asthma require an inhaled long-acting beta(2)-agonist (LABA) in addition to an inhaled corticosteroid to adequately control their disease.The purpose of this study was to assess the long-term tolerability of a salmeterol xinafoate/ fluticasone propionate (SFC) hydrofluoroalkane metered-dose inhaler (MDI) at 3 different doses BID.This 52-week, open-label, stratified, parallel-group study assessed SFC in patients with persistent asthma. Patients, aged > or = 12 years, with a diagnosis of asthma for > or = 6 months, and a percent predicted forced expiratory volume in 1 second (FEV(1)) or peak expiratory flow (PEF) between 40% and 90% were enrolled between January 1999 and June 1999. The last patient completed the 12-month study in June 2000. Patients were allowed to continue their current asthma treatment during run-in, with the exception that short-acting beta(2)-agonists (SABAs), LABAs, and oral bronchodilators were not to be used 6, 12, and 24 hours, respectively, prior to the randomization visit. During the open-label randomized treatment period, patients were instructed to discontinue all other asthma medications with the exception of the albuterol MDI to use on an as-needed basis. Patients were assigned to treatment based on their existing asthma regimen: SABA monotherapy or LABA with or without fluticasone propionate (FP) <250 microg/d or equivalent (group 1); FP 250 to 500 microg/d or equivalent with or without LABA (group 2); and FP >500 to 1000 microg/d or equivalent with or without LABA (group 3). Patients administered 2 inhalations BID of SFC hydrofluoroalkane at doses of 25/50 microg/actuation (group 1), 25/125 microg/actuation (group 2), or 25/250 pg/actuation (group 3). The primary end point was tolerability as assessed by adverse events (AEs). AEs were determined via diary cards and investigator inquiry at visits. Serious AEs were defined as death, any life-threatening event, hospitalization, disability, congenital anomaly in the patient's offspring, or other important medical events judged by the investigator to be serious. Other outcomes included clinical laboratory tests (hematology, chemistry, electrolytes), 24-hour urinary-free cortisol excretion, 12-lead electrocardiograms, oropharyngeal examinations, vital signs, clinic visit lung function tests (FEV(1) and PEF), daily diary card entries of morning PEF, and rescue medication usage.Of the 372 patients assessed for eligibility, 325 from 22 centers across Canada were enrolled and randomized to treatment. Group 1 consisted of 98 patients (55% women; 86% white; mean age, 37 years; mean [SD] weight, 79 [20] kg). Group 2 consisted of 109 patients (46% women; 94% white; mean age, 44 years; mean [SD] weight, 80 [17] kg). Group 3 consisted of 118 patients (47% women; 90% white; mean age, 45 years; mean [SD] weight, 80 [18] kg). A total of 15 adolescents (aged 12-17 years) comprised 11%, 2%, and 2% of groups 1, 2, and 3, respectively. Treatments were well tolerated, and 274 (84%) of the 325 patients enrolled completed the study. Upper respiratory tract infection was the most common AE reported: 52%, 37%, and 49% of patients in groups 1, 2, and 3, respectively. Twenty (6%) patients withdrew because of an AE, with worsening asthma being the most frequent reason (n = 9). None of the serious AEs (11 [3 %]) were considered drug related by the investigators. Improvements in FEV(1) and PEF and re- duction in symptomatic albuterol use occurred during the first 4 weeks and were maintained in all groups throughout the 52-week study.BID doses of SFC hydrofluoroalkane 50/100 pg, 50/250 pg, and 50/500 pg administered via MDI for 52 weeks were well tolerated in this population of adolescents and adults with persistent asthma." @default.
• W2040897701 created "2016-06-24" @default.
• W2040897701 creator A5004903602 @default.
• W2040897701 creator A5020174949 @default.
• W2040897701 creator A5039403104 @default.
• W2040897701 creator A5057554383 @default.
• W2040897701 creator A5081495708 @default.
• W2040897701 creator A5087705837 @default.
• W2040897701 date "2007-07-01" @default.
• W2040897701 modified "2023-10-16" @default.
• W2040897701 title "Tolerability of a Salmeterol Xinafoate/Fluticasone Propionate Hydrofluoroalkane Metered-Dose Inhaler in Adolescent and Adult Patients with Persistent Asthma: A 52-Week, Open-Label, Stratified, Parallel-Group, Multicenter Study" @default.
• W2040897701 cites W168928707 @default.
• W2040897701 cites W1902445705 @default.
• W2040897701 cites W1994078630 @default.
• W2040897701 cites W1998329899 @default.
• W2040897701 cites W2027285152 @default.
• W2040897701 cites W2063045365 @default.
• W2040897701 cites W2083269086 @default.
• W2040897701 cites W2092793338 @default.
• W2040897701 cites W2113934803 @default.
• W2040897701 cites W2121545123 @default.
• W2040897701 cites W2142653918 @default.
• W2040897701 doi "https://doi.org/10.1016/j.clinthera.2007.07.021" @default.
• W2040897701 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17825690" @default.
• W2040897701 hasPublicationYear "2007" @default.
• W2040897701 type Work @default.
• W2040897701 sameAs 2040897701 @default.
• W2040897701 citedByCount "11" @default.
• W2040897701 countsByYear W20408977012012 @default.
• W2040897701 countsByYear W20408977012013 @default.
• W2040897701 countsByYear W20408977012014 @default.
• W2040897701 countsByYear W20408977012015 @default.
• W2040897701 countsByYear W20408977012022 @default.
• W2040897701 crossrefType "journal-article" @default.
• W2040897701 hasAuthorship W2040897701A5004903602 @default.
• W2040897701 hasAuthorship W2040897701A5020174949 @default.
• W2040897701 hasAuthorship W2040897701A5039403104 @default.
• W2040897701 hasAuthorship W2040897701A5057554383 @default.
• W2040897701 hasAuthorship W2040897701A5081495708 @default.
• W2040897701 hasAuthorship W2040897701A5087705837 @default.
• W2040897701 hasConcept C126322002 @default.
• W2040897701 hasConcept C168563851 @default.
• W2040897701 hasConcept C197934379 @default.
• W2040897701 hasConcept C204243189 @default.
• W2040897701 hasConcept C2776042228 @default.
• W2040897701 hasConcept C2776719499 @default.
• W2040897701 hasConcept C2776804153 @default.
• W2040897701 hasConcept C2777419714 @default.
• W2040897701 hasConcept C2778375690 @default.
• W2040897701 hasConcept C2779028295 @default.
• W2040897701 hasConcept C2780261241 @default.
• W2040897701 hasConcept C2780667556 @default.
• W2040897701 hasConcept C2781018748 @default.
• W2040897701 hasConcept C2781212218 @default.
• W2040897701 hasConcept C42219234 @default.
• W2040897701 hasConcept C71924100 @default.
• W2040897701 hasConceptScore W2040897701C126322002 @default.
• W2040897701 hasConceptScore W2040897701C168563851 @default.
• W2040897701 hasConceptScore W2040897701C197934379 @default.
• W2040897701 hasConceptScore W2040897701C204243189 @default.
• W2040897701 hasConceptScore W2040897701C2776042228 @default.
• W2040897701 hasConceptScore W2040897701C2776719499 @default.
• W2040897701 hasConceptScore W2040897701C2776804153 @default.
• W2040897701 hasConceptScore W2040897701C2777419714 @default.
• W2040897701 hasConceptScore W2040897701C2778375690 @default.
• W2040897701 hasConceptScore W2040897701C2779028295 @default.
• W2040897701 hasConceptScore W2040897701C2780261241 @default.
• W2040897701 hasConceptScore W2040897701C2780667556 @default.
• W2040897701 hasConceptScore W2040897701C2781018748 @default.
• W2040897701 hasConceptScore W2040897701C2781212218 @default.
• W2040897701 hasConceptScore W2040897701C42219234 @default.
• W2040897701 hasConceptScore W2040897701C71924100 @default.
• W2040897701 hasIssue "7" @default.
• W2040897701 hasLocation W20408977011 @default.
• W2040897701 hasLocation W20408977012 @default.
• W2040897701 hasOpenAccess W2040897701 @default.
• W2040897701 hasPrimaryLocation W20408977011 @default.
• W2040897701 hasRelatedWork W1559467617 @default.
• W2040897701 hasRelatedWork W1985655856 @default.
• W2040897701 hasRelatedWork W1998329899 @default.
• W2040897701 hasRelatedWork W1999139619 @default.
• W2040897701 hasRelatedWork W2015366993 @default.
• W2040897701 hasRelatedWork W2020046121 @default.
• W2040897701 hasRelatedWork W2040897701 @default.
• W2040897701 hasRelatedWork W3110557464 @default.
• W2040897701 hasRelatedWork W3154998850 @default.
• W2040897701 hasRelatedWork W3199962154 @default.
• W2040897701 hasVolume "29" @default.
• W2040897701 isParatext "false" @default.
• W2040897701 isRetracted "false" @default.
• W2040897701 magId "2040897701" @default.
• W2040897701 workType "article" @default.